For patients undergoing primary total hip replacement (THR), the rate of revision varies by type of material used in the bearing surface. HealthDay News — For patients undergoing primary total hip ...

HealthDay News — Asthma is associated with memory difficulties in children, according to a study published online Nov. 11 in JAMA Network Open.

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

At-risk individuals who progress to rheumatoid arthritis (RA) have a distinctive gut microbial composition. HealthDay News — At-risk individuals who progress to rheumatoid arthritis (RA) have a ...

Researchers found in-person and self-paced online Emotional Freedom Technique programs to be a potentially effective in the management of chronic pain in adults. Intervention programs that incorporate ...

Meteorological factors accounted for less than 1% of the variation in patient-reported outcomes among individuals with psoriatic arthritis. Meteorological factors may account for less than 1% of the ...

Ciprofol, a novel propofol analogue, was favored over propofol in inducing anesthesia for colonoscopy as it resulted in lower injection pain and blood pressure reduction. In patients undergoing ...

HealthDay News — COVID-19 is associated with long-term risk for autoimmune and autoinflammatory connective tissue disorders, according to a study published online Nov. 6 in JAMA Dermatology.

A health literacy-informed digital intervention reduces the incidence of obesity at 24 months of age. HealthDay News — A health literacy-informed digital intervention reduces the incidence of obesity ...

Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.

Calcium levels decreased less with each subsequent denosumab dose among individuals with osteoporosis and advanced chronic kidney disease.

Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...